论文部分内容阅读
目的探讨鲑鱼降钙素鼻喷剂对骨质疏松症(OP)的影响。方法 100例骨质疏松症患者,随机分成观察组和对照组,各50例。两组患者均给予枸橼酸钙咀嚼片进行补钙治疗,运动、饮食宣教一致;观察组加用鲑鱼降钙素鼻喷剂喷鼻治疗。观察比较两组患者治疗前后的骨密度水平及视觉模拟评分法(VAS)评分。结果观察组治疗前后骨密度分别为(0.34±0.09)、(0.50±0.08)g/cm~2,对照组治疗前后骨密度分别为(0.35±0.07)、(0.36±0.06)g/cm~2。治疗前两组患者骨密度及VAS评分比较差异均无统计学意义(P>0.05);治疗后观察组患者的骨密度及VAS评分显著优于治疗前及对照组(P<0.05),而对照组治疗前后骨密度及VAS评分比较差异均无统计学意义(P>0.05)。结论使用鲑鱼降钙素鼻喷剂治疗骨质疏松症疗效显著,且用药方便、安全,患者依从性高,能提高患者生活质量。
Objective To investigate the effect of salmon calcitonin nasal spray on osteoporosis (OP). Methods 100 cases of osteoporosis patients were randomly divided into observation group and control group, 50 cases each. Both groups were given calcium chelate calcium citrate treatment, exercise, diet education mission; observation group plus salmon calcitonin nasal spray nasal spray treatment. The bone mineral density (BMD) and visual analogue scale (VAS) were compared between the two groups before and after treatment. Results The BMD of the observation group before and after treatment were (0.34 ± 0.09) and (0.50 ± 0.08) g / cm ~ 2 respectively. The BMD of the control group before and after treatment were 0.35 ± 0.07 and 0.36 ± 0.06 g / cm ~ . There was no significant difference in BMD and VAS score between the two groups before treatment (P> 0.05). BMD and VAS score of the observation group were significantly better than those before treatment and the control group (P <0.05) There was no significant difference in BMD and VAS score before and after treatment (P> 0.05). Conclusion Salmon calcitonin nasal spray treatment of osteoporosis significant effect, and the medication convenient, safe, patient compliance, can improve the quality of life of patients.